Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study.

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (141 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-12-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: injurymyocardialinfusionacuteinfarction
  Phrases that lowered it: healthypharmacokineticsclinicaltrialvolunteers
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports marked serious: 52.6% (lowers risk) · Drug's FDA history
• Primary purpose: prevention (lowers risk) · Design
• Sponsor's past termination rate: 9.5% (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 6.1% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports before start: 110342 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Intracoronary N-Acetylcysteine in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention NCT06850831 · started 2025 · scored riskier than 52% of active trials completed
• A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study NCT02429271 · started 2015 · scored riskier than 61% of active trials completed
• Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction NCT01374321 · started 2011 · scored riskier than 95% of active trials completed
• A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI NCT04023266 · started 2019 · scored riskier than 86% of active trials completed
• Myocardial Protection With Adenosine During Primary Percutaneous Coronary Intervention in Pts With STEMI NCT00781404 · started 2008 · scored riskier than 24% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.